MN, et al. N Engl J Med. 2023;388(8):719-732. [8]Matthew R Smith,et al. Lancet Oncol. 2022 Mar;23
A Randomized Clinical TrialDon Laing, MBChB1; Eamon P. G. Walsh, BMedSc1; Jane M. Alsweiler, PhD2,3
会议视频参考文献[1] John T, et al. Molecular residual disease (MRD)(adj) osimertinib in patients (pts) with